The beleaguered Belgian firm Galapagos is splitting itself into two companies, with the brandname biotech prioritizing ...

U.S.-listed shares rose over 4% in Wednesday's premarket after it announced a significant restructuring plan, including a ...

In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Galapagos (GLPG – Research Report), with a price ...

Belgian biotech company Galapagos NV plans to spin off part of its operations, creating a new listed firm with approximately ...

Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with ...

TD Cowen cut shares of Galapagos (NASDAQ:GLPG – Free Report) from a strong-buy rating to a strong sell rating in a report released on Thursday,Zacks.com reports. Other equities analysts also recently ...

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667 ...

In a report released today, Emily Field from Barclays maintained a Hold rating on Galapagos (0JXZ – Research Report), with a price target of ...

Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain ...

CET; Galapagos NV. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.In addition, Galapagos ...

Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 pm PT in San Francisco ...